Clinical trial
Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer
NCT00065533 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00065533 |
|---|---|
| Title | Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer |
| Official title | Study of Two Doses of ALIMTA (Pemetrexed) as First Line Chemotherapy for Advanced Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed |
| Enrollment | 92 |
| Start date | May 1, 2003 |
| Completion | Jun 1, 2005 |
| First posted | Jul 29, 2003 |
| Last update posted | Jun 22, 2007 |
| Countries | Argentina, Belgium, Germany, Romania, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: